Beam Therapeutics BEAM Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1

Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 at other companies

Beam TherapeuticsBEAM

$1.93M—

Fulton FinancialFULT

$0-100%

MarketAxessMKTX

$455.5K—

StoneX Group Inc.SNEX

$7.2M+22.0%

FCF

FirstCash HoldingsFCFS

$27.01M—

Intuitive Machines, Inc.LUNR

$874.75K—

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.42B+24.5%

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1.

The official record: Beam Therapeutics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's noncash or part noncash acquisition value of liabilities assumed1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's noncash or part noncash acquisition value of liabilities assumed1?: Beam Therapeutics (BEAM) reported noncash or part noncash acquisition value of liabilities assumed1 of $1.93M in Q4 2025.
What does noncash or part noncash acquisition value of liabilities assumed1 mean?: Represents the value of liabilities assumed by the company during a business acquisition that did not involve an immediate cash outlay. This metric provides transparency into the total purchase price and the structure of acquisition-related debt or obligations. It is essential for evaluating the true cost and financing structure of inorganic growth strategies.